Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...
Pharmabiz1d
Quanta receives US FDA clearance to begin phase 1 trial of QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor
Quanta receives US FDA clearance to begin phase 1 trial of QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor: Radnor, Pennsylvania Friday, January 10, 2025 ...
Pharmaceutical Technology5d
QTX-3046 by Quanta Therapeutics for Colorectal Cancer: Likelihood of Approval
QTX-3046 is under clinical development by Quanta Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 7 ...
Business Wire1mon
NextRNA Therapeutics Appoints Seasoned Industry Leader Charles Kunsch, Ph.D. to Board of Directors
Accent Therapeutics and Quanta Therapeutics, among others. Prior to AbbVie, Dr. Kunsch served as Vice President of Biology at AtheroGenics, Inc., where he led teams to advance several programs ...
Yahoo Finance19d
Quantum eMotion Deploys its Quantum-Safe Security Platform for Digital Therapeutics in Landmark Commercial Alliance
As the digital therapeutics field continues to revolutionize ... QeM has become a pioneering force in classical and quantum cybersecurity solutions thanks to its patented Quantum Random Number ...
Pharmaceutical Technology5d
QTX-3046 by Quanta Therapeutics for Lung Cancer: Likelihood of Approval
QTX-3046 is under development for the treatment of solid tumor, colorectal, pancreatic, endometrial cancer and lung cancer. It is administered through oral route. The drug candidate acts by targeting ...